Abstracts

Citation

Sharon Appelbaum Nachman, M.D., Pearl Samson, M.S., Lisa M. Frenkel, M.D., Edward P. Acosta, Pharm.D., Hedy Teppler, M.D., Terence Fenton, Ed.D., Edward Handelsman, M.D., Carol J. Worrell, M.D., Bobbie L. Graham, B.S., Andrew A. Wiznia, M.D. A Phase I/II, Multicenter, Open-Label, Noncomparative Study to Evaluate Raltegravir (RAL) in HIV-1 Infected Youth. Presented at: 49th Intersci Conf on Antimicrobial Agents & Chemotherapy.

Citation

Sharon Appelbaum Nachman, M.D., Pearl Samson, M.S., Lisa M. Frenkel, M.D., Edward P. Acosta, Pharm.D., Hedy Teppler, M.D., Terence Fenton, Ed.D., Edward Handelsman, M.D., Carol J. Worrell, M.D., Bobbie L. Graham, B.S., Andrew A. Wiznia, M.D. 24 Week Safety and efficacy from IMPAACT P1066: A Phase I/II, Multicenter, Open-Label, Noncomparative Study to Evaluate Raltegravir (RAL) in HIV-1 Infected Youth. Presented at: 49th Intersci Conf on Antimicrobial Agents & Chemotherapy.

Citation

Nevirapine vs Kaletra for treatment of single dose Nevirapine-exposed HIV-infected infants: preliminary results from IMPAACT P1060. Presented at: 5th IAS Conf on HIV Pathogenesis, TX & Prevention.

Citation

Anneke C. Hesseling, Soyeon Kim, Ph.D., Shabir A. Madhi, M.D., Sharon Appelbaum Nachman, M.D., Hendrik Simon Schaaf, MB ChB, Thomas C. Victor, Charles Debeaux Mitchell, M.D., Avy Violari, M.D., George D. McSherry, M.D., Mark F. Cotton, MMED, Ph.D., MB ChB. High prevalence of drug resistance amongst HIV-exposed and infected children with culture confirmed tuberculosis enrolled on a tuberculosis prevention trial. Presented at: 5th IAS Conf on HIV Pathogenesis, TX & Prevention.

Citation

Paul Palumbo, M.D., Avy Violari, M.D. Nevirapine (NVP) vs lopinavir-ritonavir (LPV/r)-based antiretroviral therapy (ART) in single dose nevirapine (sdNVP)-exposed HIV-infected infants: preliminary results from the IMPAACT P1060 trial. Presented at: 5th IAS Conf on HIV Pathogenesis, TX & Prevention.

Citation

Wasana Prasitsuebsai, M.D., Tim Roy Cressey, B.Sc., Ph.D., Nirun Vanprapar, M.D., M.Sc., Edmund Capparelli, Pharm.D., Linda Aurpibul, M.D., Virat Sirisanthana, M.D., Petronella Muresan, M.S., Chanin Limwongse, M.D., Achara Eksaengsri, B.Pharm., Elizabeth (Betsy) Smith, M.D., Kenneth McIntosh, M.D., Ram Yogev, M.D., Kulkanya Chokephaibulkit, M.D. A novel chewable pediatric fixed-dose combination (FDC) of zidovudine (ZDV), lamivudine (3TC), nevirapine (NVP): pharmacokinetics and safety in HIV-infected Thai children. Presented at: International Workshop on HIV Pediatrics.

Citation

Kristina Brooks, Jennifer Kiser, Pearl Samson, Yasha Rani, Shawn Ward, Timothy Cressey, Haseena Cassim, Jaime Deville, Gaerolwe Masheto, Ponego Ponatshego, Anne Coletti, Kathryn Lypen, Iris Mustich, Barbara Heckman, Mark Lojacono, Rachel Bowman, Dwight Yin, Ellen Townley, Sai Majji, Edward Acosta, Annie Buchanan, Cindy Brothers, Hardik Chandasana, Helena Rabie, Patricia Flynn, IMPAACT 2019 Team. Pharmacokinetics and Safety of Dispersible and Immediate Release FDC Abacavir/ Dolutegravir/ Lamivudine in Children with HIV Weighing =14 kg: Preliminary Results from IMPAACT 2019. Presented at: International Workshop on HIV Pediatrics; 2021 Jul 16.

Citation

Tapiwa Mbengeranwa, Lauren Ziemba, Benjamin Johnston, Haseena Cassim, Gerhard Theron, Z. Ngqawana, Deo Wabwire, Katie McCarthy, Nahida Chakhtoura, Patrick Jean-Philippe, John Shepherd, Shahin Lockman, Lameck Chinula, Lynda Stranix-Chibanda, IMPAACT 2010/VESTED Study Team and investigators. Bone mineral density/content of postpartum mothers taking treatment including DTG vs EFV, TDF vs TAF in pregnancy and their infants: randomized IMPAACT 2010 trial. Presented at: International Workshop on HIV Pediatrics; 2021 Jul 16.

Citation

Kimberly Shankwitz, Lesley de Armas, Alexander Kizhner, Suresh Pallikkuth, Rajendra Pahwa, Grace Montepiedra, Mauricio Pinilla, Amita Gupta, Savita Pahwa, Jyoti Mathad. The Effect of HIV and Latent Tuberculosis Infection During Pregnancy on Infant Immune Development in IMPAACT P1078 study cohort. Presented at: International Workshop on HIV Pediatrics.

Citation

Tim R. Cressey, Adrie Bekker. Abacavir Weight-Band Dosing for Infants in the first 4 weeks of life. Presented at: International Workshop on HIV Pediatrics; 2021 Jul 16.